Standard BioTools Inc. (LAB)
NASDAQ: LAB · Real-Time Price · USD
1.400
-0.070 (-4.76%)
At close: Jul 25, 2025, 4:00 PM
1.360
-0.040 (-2.86%)
After-hours: Jul 25, 2025, 5:31 PM EDT
Standard BioTools Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Standard BioTools stock have an average target of 2.5, which predicts a 78.57% increase from the current stock price of 1.4.
Price Target: $2.5 (+78.57%)
Analyst Consensus: Buy
* Price targets were last updated on Oct 31, 2024.
Analyst Ratings
The average analyst rating for Standard BioTools stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Feb '25 | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 1 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 3 | 3 | 3 | 3 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Keybanc | Keybanc | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Feb 27, 2025 |
| TD Cowen | TD Cowen | Strong Buy Maintains $2.75 → $2.5 | Strong Buy | Maintains | $2.75 → $2.5 | +78.57% | Oct 31, 2024 |
| TD Cowen | TD Cowen | Strong Buy Maintains $3.5 → $2.75 | Strong Buy | Maintains | $3.5 → $2.75 | +96.43% | Aug 1, 2024 |
| TD Cowen | TD Cowen | Strong Buy Initiates $3.5 | Strong Buy | Initiates | $3.5 | +150.00% | Apr 16, 2024 |
| Jefferies | Jefferies | Strong Buy Initiates $3.25 | Strong Buy | Initiates | $3.25 | +132.14% | Apr 4, 2024 |
Financial Forecast
Revenue This Year
170.84M
from 174.43M
Decreased by -2.06%
Revenue Next Year
191.64M
from 170.84M
Increased by 12.18%
EPS This Year
-0.28
from -0.52
EPS Next Year
-0.17
from -0.28
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 180.0M | 204.8M | 221.0M | |
| Avg | 170.8M | 191.6M | 209.0M | |
| Low | 161.7M | 182.7M | 199.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|
| High | 3.2% | 19.8% | 15.3% | |
| Avg | -2.1% | 12.2% | 9.0% | |
| Low | -7.3% | 6.9% | 4.0% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -0.25 | -0.09 | -0.03 |
| Avg | -0.28 | -0.17 | -0.03 |
| Low | -0.30 | -0.24 | -0.03 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.